Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment

NCT06682988 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06682988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06682988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
May 28, 2025
Completion date
April 30, 2028
Enrollment
110 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

advanced high-grade epithelial ovarian cancer, fallopian tube cancers, primary peritoneal cancer